Susanna Naggie

Susanna Naggie serves as Vice Dean for Clinical and Translational Research and Director of the Duke Clinical and Translational Science Institute (CTSI) at Duke University School of Medicine, where she holds a Professor of Medicine position. She spearheads institutional clinical research strategy, overseeing the Duke Office of Clinical Research and Office of Regulatory Affairs & Quality while collaborating with campus-wide leadership including the Duke Clinical Research Institute.

Education:

• MD from Johns Hopkins School of Medicine
• Internal Medicine training and Chief Residency at Duke University
• Infectious Diseases fellowship at Duke University

As a physician-scientist, Dr. Naggie's research centers on HIV and viral hepatitis co-infections with emphasis on liver fibrogenesis mechanisms and biomarker development. Her work spans translational hepatology, clinical trial innovation, and health equity in infectious disease management. She actively contributes to national guideline panels addressing HIV, hepatitis B/C, and opportunistic infections.

Recent publications (2022-2025) reveal dominant themes in HIV/hepatitis co-infection liver pathology, minimal-monitoring HCV treatment strategies, and community-engaged research methodologies. Her leadership in the ACTIV-6 platform for outpatient COVID-19 therapeutics and the READI initiative for research equity demonstrates commitment to pragmatic trial design and inclusive participant engagement.

No scientific awards were explicitly mentioned in source materials.

Dr. Naggie directs the Duke CTSI infrastructure while leading major initiatives including the MINMON HCV trial and ACTIV-6 platform. Her oversight of the Duke Office of Clinical Research and Clinical Research Units facilitates cross-departmental collaboration and regulatory support for investigator-initiated studies.

She leads the Duke Clinical and Translational Science Institute with integrated teams spanning the Division of Infectious Diseases, hepatology research groups, and community partnerships like Duke Research at Pickett focused on health equity advancement through decentralized trial methodologies.